NMD Pharma is a clinical-stage biotech company focused on developing first-in-class, small molecule ClC-1 inhibitors targeting muscle function within neuromuscular disorders. Their initial focus is on diseases such as myasthenia gravis, spinal muscular atrophy, Charcot-Marie Tooth’s disease, and sarcopenia.

NMD Pharma A/S

MissionNMD Pharma is dedicated to developing novel treatments to improve muscle function and quality of life of patients with neuromuscular disease.VisionA future in which patients with neuromuscular disease live better and more independent lives.We have a unique translational muscle electrophysiology platform leveraging in-depth know-how of muscle physiology and muscular disorders for discovering and developing first-in-class therapeutics in neuromuscular diseases with a significant unmet medical need.NMD Pharma is the leading company utilizing ClC-1 Cl- ion channel inhibitors for neuromuscular diseases and currently has one clinical-stage product candidate for the treatment of myasthenia gravis.We have more than 25 employees with expertise in all areas of drug development. We are headquartered in Aarhus, Denmark, and collaborate with internationally renowned companies and key opinion leaders in the field of neuromuscular diseases.For more information, please visit the company website.

COM:NMDPHARMA

NMD Pharma A/S

locale

market

industry

website

crunchbase

linkedin

founding date

invested in

investor of

Metrics